SEC comment letter
Filing comparison
SEC staff questioned Annovis Bio, Inc.'s accounting for MD&A
Letter dated 2025-09-04; published on EDGAR 2026-02-24 — the SEC releases comment letters only after the review closes.
We note your statement on page 82 that you "track and record information regarding external research and development expenses for each study or trial that we conduct." However, you have not provided such a breakout on page 83, nor have you quantified, in the accompanying explanation, the changes in the several factors identified as having contributed to the consolidated change. Given research and development (R&D)…
Evidence
- Direction
- staff to company
- Letter dated
- 2025-09-04
- Published on edgar
- 2026-02-24
- Reviewing
- Annovis Bio, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 21, 2025 File No. 001-39202 Dear Maria Maccecchini: We have limited our revi
- Source
- SEC staff comment letter (UPLOAD)
- Topics
- MD&A
- Why
- SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.